Duncan Bucknell
Strategic Intellectual Property
Strip the case names away and one pattern runs through this month’s posts: the decisive moment in an IP matter almost never happens in the courtroom. It happens years earlier —...
The latest Federal Budget reshapes the operating environment for IP‑intensive businesses in ways that go well beyond tax. Refundable R&D offsets for younger firms, the removal of supporting R&D categories, and...
Last week a US federal judge delaying final approval of Anthropic’s proposed US$1.5B copyright settlement with authors and publishers over alleged use of pirated books in training its Claude models. The...
The Davies v Lazer Safe decision is a timely reminder that in IP disputes, leverage often sits in the procedural details. The Court clarified that an old filing restriction—tied to documents...
Another Repatha instalment, this time the UPC (Unified Patents Court) in Europe issued it’s first decision on infringement of second medical use claims. Regeneron’s EP 3536712 patent (licensed to Sanofi) found...
“‘The technology is moving so fast and we’re so small, we don’t need a patent, we just need to move fast.” Wrong. Every small tech company is going to want to...
Another quick excerpt from the new book, Pharmaceutical, Biotechnology and Chemical Inventions: World Protection and Exploitation published by Oxford: “It is quite common in the fields dealt with in this text for...
Oxford University Press doesn’t do things by halves. A beautiful looseleaf they sent over recently for me to review is no exception to this rule. It’s called ‘Drafting Agreements in the...
Here are some notes from the presentation given by Duncan on Global IP Strategy on 30 July (Europe and US) / 31 July (Australia), ably hosted by Jim Bergman from IACCM....
You must be logged in to post a comment.